Medico Remedies Ltd. (MEDICO) — Tipsheet https://tipsheet.markets/company/medico/ Every Tipsheet Editorial note covering Medico Remedies Ltd. (MEDICO), newest first. Grounded in BSE/NSE primary-source filings. en-in Mon, 06 Jul 2026 10:22:48 GMT Medico Remedies' credit line more than doubles to ₹42 cr, rating reaffirmed https://tipsheet.markets/medico-medico-remedies-credit-line-more-than-doubles-to-42-cr-rating-reaffirmed-116389/ https://tipsheet.markets/medico-medico-remedies-credit-line-more-than-doubles-to-42-cr-rating-reaffirmed-116389/ Mon, 29 Jun 2026 18:14:30 GMT CRISIL reaffirms BBB-/Stable while enhancing rated facilities by ₹23 cr, a key capacity move for a nano-cap exporter with 37% revenue growth. CRISIL reaffirms BBB-/Stable while enhancing rated facilities by ₹23 cr, a key capacity move for a nano-cap exporter with 37% revenue growth.

What’s new

  • CRISIL reaffirmed Medico's long-term rating at BBB-/Stable and short-term at A3.
  • Rated facilities more than doubled from ₹19 cr to ₹42 cr across term loan, packing credit, and LC.
  • The ₹23 cr increase equals over 12.5% of the company's ₹335 cr market capitalisation.

Why it matters

For a nano-cap pharma exporter, doubling sanctioned credit lines signals bank confidence and provides working capital headroom to support rapid revenue growth. The additional ₹23 cr is meaningful against trailing revenue of ₹206 cr.

What we’re watching

  • Whether Medico uses the extra borrowing capacity to boost exports (which make up the bulk of sales).
  • Impact on the already low debt/equity ratio of 0.22.
  • Any follow-on order wins that capitalise on the expanded facilities.

The full read

Medico Remedies just got a significant vote of confidence from its bankers and from CRISIL. The rating agency reaffirmed the BBB-/Stable long-term rating, but the real news is the credit line. Rated facilities more than doubled from ₹19 crore to ₹42 crore, a ₹23 crore jump representing over 12.5% of Medico's ₹335 crore market cap. For a nano-cap pharma exporter with trailing revenue growth of 37% and a debt/equity of just 0.22, this is not a routine reaffirmation. It is a capacity upgrade. The facilities from Kotak Mahindra Bank include term loan, packing credit, and LC, directly supporting export order execution. With FY26 revenue of ₹206 cr and exports dominating, the extra headroom could help Medico seize larger or faster-turn orders. The open question: will it use the line to push growth further or simply as a buffer? The stable rating suggests CRISIL sees the continued strength in the business.

Primary source: BSE · NSE

]]> Credit Tipsheet Editorial Medico Remedies closes FY26 with 37% revenue growth, no surprises https://tipsheet.markets/medico-medico-remedies-closes-fy26-with-37-revenue-growth-no-surprises-94435/ https://tipsheet.markets/medico-medico-remedies-closes-fy26-with-37-revenue-growth-no-surprises-94435/ Thu, 21 May 2026 17:46:19 GMT Audited numbers confirm export-driven momentum but offer no new catalyst for a nano-cap that had already telegraphed its trajectory. Audited numbers confirm export-driven momentum but offer no new catalyst for a nano-cap that had already telegraphed its trajectory.

What’s new

  • Revenue rose 37% YoY to ₹206.38 cr, net profit up 30% to ₹13.12 cr.
  • Audit opinion unmodified; no exceptional items or guidance changes.
  • Results are a routine confirmation of already-anticipated performance.

Why it matters

For a nano-cap, the growth is solid, but the filing is a regulatory formality. The export-led momentum has been visible for quarters, and with no surprise or guidance revision, this is a non-event for the market.

What we’re watching

  • Whether export orders sustain in FY27 as the base widens.
  • Any margin or capacity updates in the coming quarters.

The full read

Medico Remedies closed FY26 with revenue of ₹206.38 crore, up 37% year-on-year, and net profit of ₹13.12 crore, up 30%. The numbers are a clean confirmation of the export-driven growth telegraphed through prior quarterly disclosures. An unmodified audit opinion and the absence of exceptional items or guidance changes make this a routine regulatory filing rather than a catalyst. The next test is whether the same pace is sustainable as the base widens in FY27. For now, the company delivered what it said it would — no more, no less.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial